[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613918":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":31,"collaborators":7,"id":33,"slug":7,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":7,"studyType":46,"phases":7,"briefSummary":47,"conditions":48,"keywords":54,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"University of Alberta","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Krista Jong, RD, BSc","CONTACT","780-492-9010","glimmer@ualberta.ca",[15],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Mazankowski Alberta Heart Institute","RECRUITING","Edmonton","Alberta","T6G 0M9","Canada",{"type":23,"coordinates":24},"Point",[25,26],-113.46871,53.55014,{"lat":26,"lon":25},[29],{"name":30,"role":11,"phone":12,"phoneExt":7,"email":13},"Krista Jong",{"type":32,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100613918",false,"NCT07272837","Impact of Semaglutide (Ozempic\u002FWegovy®) on Heart and Muscle Mass","GLP-1 Receptor Agonist-Induced Loss and Impairment of Muscle Mass - Evaluation of Response","GLIMMER","Inclusion Criteria:\n\n* Adults 18-80 years of age\n* Starting semaglutide for type 2 diabetes or weight loss\n* Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)\n\nExclusion Criteria:\n\n* Current use of semaglutide for more than 2 weeks\n* Major recent heart issues or other severe health conditions\n* Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)\n* Dependence on a mobility aid (unable to participate in exercise MRI)","ALL","18 Years","80 Years",{"count":44,"type":45},50,"ESTIMATED","OBSERVATIONAL","The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.\n\nThis study involves (3) in-person study visits. At each visit, participants will be asked to:\n\n* Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.\n* Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.\n* Complete questionnaires related to demographics, health information, physical activity, and nutrition.\n* Have a blood sample collected from a vein in your arm.\n* Have your blood levels assessed through three finger pricks.\n* Complete three days of food records.",[49,50,51,52,53],"Type 2 Diabetes","Obesity","Semaglutide","GLP-1","Diabetes",[51,49,53,50,55,56,57,58,59,52,60,61],"Body Composition","Muscle Mass","Skeletal Muscle Mass","Cardiac Muscle Mass","GLP-1 Receptor Agonist","MRI","Magnetic Resonance Imaging","2026-04-15",{"date":64,"type":65},"2026-04-20","ACTUAL",{"date":67,"type":45},"2026-04-14",{"date":69,"type":45},"2028-04-30",{"name":5,"class":6},1]